Compare iShares US Power Infrastructure ETF (POWR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares US Power Infrastructure ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares US Power Infrastructure ETF trades at $24.99 (market cap $448.01M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 10.9× iShares US Power Infrastructure ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Power Infrastructure ETF for 19 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| POWR | TVTX | |
|---|---|---|
Market Cap | $448.01M | $4.88B |
Volume | 115,109 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $28.22 | $67.52 |
52-Week Low | $23.20 | $26.79 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
POWR trades at $25.68, up 0.75% with a bullish technical signal from moving averages. The company reported $256.66M revenue in 2014 but posted a net loss of -$6.99M, with negative EBITDA of -$952K. Cash flow trends show volatility, with 2014 net cash flow at -$17.14M. The stock faces fundamental challenges despite technical strength, with debt-to-asset ratio at 7.09 indicating high leverage.
The outlook remains mixed with technical indicators supporting near-term upside, but fundamental weaknesses in profitability and cash flow generation pose significant risks. Investment opportunity exists if operational improvements materialize, while current financial metrics suggest caution for value-oriented investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares US Power Infrastructure ETF
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
